Exercise Training for Exercise Responses

Overseen By TRAVIS D GIBBONS, PhD

Age: 18 - 65

Sex: Any

Trial Phase: Phase < 1

Sponsor: Northern Arizona University

Must not be taking: Anti-hypertensives, Anti-arrhythmogenics, Blood thinners

Disqualifiers: Smokers, Asthma, Diabetes, Obesity, others

Compensation: Varies

Number of Visits: Unknown

Duration: 2 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

Exercise places serious demands on the body. These demands are fundamentally caused by increases in oxygen demand and the consequent increase in body temperature. These demands are met by several physiological responses, including increases in heart rate, blood pressure, breathing and blood flow. These responses must be proportional to the increase in demand and some signal must relay information from the muscle to the brain. Group III/IV afferents do just this. They relay information about the muscle (movement, temperature, acidity, etc.) up to the brain so that appropriate responses are mounted. There is strong evidence in animals that group III/IV afferents play a key role in making breathing easier (decreasing airway resistance) and initiating sweating and blood flow responses. There has been no research on the role of group III/IV afferents on these fundamental exercise responses in humans. The investigators propose to isolate the role of group III/IV afferents on regulate airway resistance, sweating and blood flow responses to exercise in humans.

Who Is on the Research Team?

TRAVIS D GIBBONS, PhD

Principal Investigator

Northern Arizona University

Are You a Good Fit for This Trial?

Inclusion Criteria

Regularly physically active as determined via questionnaires (Par-Q & You)

Maximal aerobic power 30 mL/min/kg (female), 40 mL/kg/min (male)

Exclusion Criteria

Current smokers

History of drug abuse

I have chronic lung disease like COPD or severe asthma.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants exercise on two different occasions, one with intact muscle reflex feedback, and the other with feedback suppressed using intrathecal opioids

2 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

How Is the Trial Designed?

Group I: Group III/IV afferent blockade Experimental Treatment 1 Intervention

Feedback from group III/IV afferents is blocked

Group II: Placebo-control Placebo Group 1 Intervention

Exercise with saline injection

Who Is Running the Clinical Trial?

Northern Arizona University

Lead Sponsor

Trials

36

Recruited

6,300+